newsletter3

banner-keypub

Key Publications and Scientific Videos

suPAR Publications and links
Please always find our latest list of suPAR Publications and links to PubMed here:
  suPAR Pub Med Publications and Links 2009-2017

The same PubMed list grouped by Organ and Disease here:
  suPAR Pub Med Publications and Links - Organ and Disease grouped

suPAR Monograph
NEW - ON THE BASIS OF MORE THAN 400 PUBLISHED ARTICLES ON suPAR IN PubMed, A suPAR MONOGRAPH HAS BEEN WRITTEN.
Here you can find a short summary of the research done on suPAR within 12 groups of disease areas, and see how the suPAR level is affected within each kind of disease.

Please find the suPAR Monograph here:

suPAR Monograph pdf pdf icon suPAR Monograph (English)

pdf icon suPAR Monografi (Danish)

pdf icon suPAR Monografia (Spanish)

suPAR scientific videos
Please go to the suPARnostic You Tube channel

https://www.youtube.com/user/suPARnostic 

to find all our scientific videos including selected presentations from our suPAR Symposias.

KEY SUPAR PUBLICATIONS


September 2, 2016:

"suPAR in acute care: A strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study" was publisehd online in EMJ, Emergency Medical Journal in September 2016.

The study included 4343 consecutively admitted patients from the AMU at a large Danish university hospital (Hvidovre).

The conclusion is again, that in an unselected population of acute medical patients;
"A high suPAR level upon admission to the AMU is a marker of severe disease and increased risk of readmission and mortality after adjusting for all other risk factors .... and suPAR adds information to established prognostic indicators".

Patients with low suPAR levels have low risk of readmission and mortality, while patients with high suPAR levels have a high risk of adverse events.

Please find the publication by Line J.H.Rasmussen et al from EMJ here

November 10, 2015:
A study in the New England Journal of Medicine published on November 5 shows that suPAR reliably can predict the development of Chronic Kidney Disease up to five years before symptoms of this disease emerge - a disease that affects an estimated 600 million people.

Currently, physicians rely on two markers to monitor existing kidney disease, but they are not sensitive enough to predict a persons risk of developing the disease or to catch it in its early stages.

The New England Journal of Medicine study found that a high suPAR level was an excellent predictor of future kidney disease.
"We can now stratify people according to their risk of developing kidney disease using suPAR levels" said Dr. Salim Hayek, first author of the study.

The study is even a significant breakthrough in preventive medicine. Also diabetes patients, of which about one-third develop Diabetic Kidney Disease, can now be helped.
"This will help risk-stratify patients with diabetes on their risk of future kidney disease" explains Jochen Reiser, senior author of the NEJM study.

Results are based upon research using the suPARnostic® products from ViroGates.

The New England Journal of Medicine article and abstract
http://www.nejm.org/doi/full/10.1056/NEJMoa1506362

An editorial explaining and commenting on the data
http://www.nejm.org/doi/full/10.1056/NEJMe1512997?rss=searchAndBrowse

ScienceDaily comment on the data set
http://www.sciencedaily.com/releases/2015/11/151105151925.htm

December 1, 2014:
New data from a Danish Interventional Study done at Hillerød University Hospital Denmark incl. 6000 patients

The prize winning poster titled "suPAR – A future prognostic biomarker in Emergency Medicine" was presented and awarded in the 6th Danish Emergency Medicine Conference, november 2014.

Data are based on all medical patients coming to the Emergency Room (ER), and are thus very representative for the most common diseases seen in any Emergency Room incl. not only bacterial or viral infections but also CVD, cardiac cases, lung diseases and comorbidities.
In this wide cohort, suPAR (ELISA) testing gives an 0.85 AUC value for prognosing survival, which is much stronger than CRP and the prognosis provided in the DEPT Triage system.

Data shows that the current Danish Emergency Process triage system needs to be improved with a prognostic biomarker evaluation -  and suPAR is the best choice!

The conclusion is clear:
"In unselected patients admitted to an Emergency Department, suPAR is an independant marker of short-term mortality.

suPAR could potentially help clinicians in the initial risk assessment of acutely admitted patients".

Please find the poster titled "suPAR – A future prognostic biomarker in Emergency Medicine" - here